Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

APGEBullishM&Anews

High materiality8/10

AbbVie to Acquire Apogee Therapeutics for $10.9B in Cash

Jun 22, 2026, 12:26 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The cash offer creates a guaranteed exit price for APGE holders and immediate upside relative to pre-announcement levels. Historically, such deals push target stocks toward the offer price, though closing risk and regulatory timelines can cap gains if delays arise or deal fails.

AI summary

What happened, with direct paths to the underlying reporting

AbbVie will acquire Apogee Therapeutics in a cash deal valued at about $10.9 billion at $135.11 per APGE share. APGE surged 46.8% to $132.66 on Thursday, signaling strong bidder premium expectations. Near-term catalysts are regulatory approvals and closing; if completed, APGE shareholders receive cash and the company exits public trading.

APGE to be acquired by AbbVie in a cash deal valued at $10.9B.
Offer price $135.11 per share.
APGE stock surged 46.8% to $132.66 on Thursday.
Deal advances AbbVie's pipeline expansion; regulatory approvals pending.
Cash deal implies immediate value realization for APGE holders.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.